These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31062821)

  • 1. Editorial: Failure After Failure. What Next in AD Drug Development?
    Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):150. PubMed ID: 31062821
    [No Abstract]   [Full Text] [Related]  

  • 2. New Hope for Alzheimer's Disease.
    Vellas B; Aisen P
    J Prev Alzheimers Dis; 2021; 8(3):238-239. PubMed ID: 34101778
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.
    Schneider LS
    J Prev Alzheimers Dis; 2020; 7(3):199-200. PubMed ID: 32463075
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug for mild AD enters next wave of study.
    J Gerontol Nurs; 2013 Feb; 39(2):10. PubMed ID: 23368285
    [No Abstract]   [Full Text] [Related]  

  • 5. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 6. Alzheimer's disease: expedition into the unknown.
    The Lancet
    Lancet; 2016 Dec; 388(10061):2713. PubMed ID: 27924761
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Hershey LA; Tarawneh R
    Neurology; 2021 Sep; 97(11):517-518. PubMed ID: 34233940
    [No Abstract]   [Full Text] [Related]  

  • 8. Lecanemab trial in AD brings hope but requires greater clarity.
    Thambisetty M; Howard R
    Nat Rev Neurol; 2023 Mar; 19(3):132-133. PubMed ID: 36609712
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: How Will Aducanumab Approval Impact AD Research?
    Weiner MW; Aisen PS; Beckett LA; Green RC; Jagust W; Morris JC; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ
    J Prev Alzheimers Dis; 2021; 8(4):391-392. PubMed ID: 34585209
    [No Abstract]   [Full Text] [Related]  

  • 10. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
    Sacks CA; Avorn J; Kesselheim AS
    N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: Establishing a Trial Ready Cohort to Accelerate Alzheimer's Clinical Trial Enrollment and Treatments.
    Meyers EA; Carrillo MC
    J Prev Alzheimers Dis; 2020; 7(4):202-203. PubMed ID: 32920618
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 13. Participant Satisfaction With Learning Alzheimer Disease Clinical Trial Results.
    Pierce AL; Cox CG; Nguyen HT; Hoang D; Witbracht M; Gillen DL; Grill JD
    Alzheimer Dis Assoc Disord; 2018; 32(4):366-368. PubMed ID: 29683808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failed Alzheimer's trial does not kill leading theory of disease.
    Abbott A; Dolgin E
    Nature; 2016 Nov; 540(7631):15-16. PubMed ID: 27905452
    [No Abstract]   [Full Text] [Related]  

  • 15. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pivotal trials for β-secretase inhibitors in Alzheimer's.
    Sheridan C
    Nat Biotechnol; 2015 Feb; 33(2):115-6. PubMed ID: 25658256
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid plaques are still main target for Alzheimer's drugs.
    Hawkes N
    BMJ; 2016 Jan; 352():i214. PubMed ID: 26762356
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: Alzheimer's Disease Drug Development Pipeline 2020.
    Sabbagh MN
    J Prev Alzheimers Dis; 2020; 7(2):66-67. PubMed ID: 32236392
    [No Abstract]   [Full Text] [Related]  

  • 20. Biogen's early Alzheimer's data raise hopes, some eyebrows.
    Ratner M
    Nat Biotechnol; 2015 May; 33(5):438. PubMed ID: 25965736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.